Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

Yellow4FLAVI Deconstructing the protective immunity of yellow fever virus 17D to inform flavivirus vaccine design

Coordinator
Institut Pasteur, France
Runs
1 January 2024 to 31 December 2028
Status
Running
EU funding
€8.5m
Total cost
€8.5m
Partners
15 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101137459

What the project is doing

In the project's own words, from its summary on CORDIS.

While endemic to the tropics, flaviviruses like Zika, dengue, West Nile or yellow fever virus are re-emerging pathogens of global health concern. Climate change and urbanization have largely contributed to the dissemination of their mosquito vector and Europe has in recent years been regularly confronted with autochthonous cases. Few vaccines are licensed to prevent flavivirus disease, but the yellow fever 17D (YF17D) vaccine has a unique track record of efficiency and safety.

Intriguingly, despite its success, how YF17D induces immunity remains poorly understood. The YELLOW4FLAVI consortium aims to fill the gaps in our understanding of the mechanism of action of this vaccine by linking the structure of the viral particle to the resulting host immune response, in order to learn about optimal vaccine design for flaviviruses in general. Since social acceptance of vaccines is critical for their success, we will also develop optimal communication methods.

This will provide us with the tools to tailor vaccine design not only to achieve optimal immune protection, but also to facilitate actual implementation. We are molecular and structural virologists, cell biologists, immunologists, computational scientists, clinicians, and social scientists assembled in a tight collaborative network. To pursue our goal of obtaining a blueprint for determinants of long-lasting immunity for flavivirus vaccine candidates, we will use cutting-edge technologies like cryo-EM, super resolution microscopy, spatial transcriptomics, high-dimensional spectral flow cytometry, single-cell RNA sequencing, advanced cell engineering, small animal models, and clinical studies.

In a unique manner, the consortium thereby follows a thread of events from the early response at the site of vaccine injection to the population perception of vaccination, harnessing an enhanced understanding of one of the most successful vaccines of mankind for the development of novel lines of defense against new and old threats.

Who is involved

OrganisationCityCountryRole
Institut PasteurParisFranceCoordinator
Immunewatch BVAntwerpenBelgiumParticipant
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Corporacion Centro Internacional De Entrenamiento E Investigaciones MedicasCaliCOParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Klinikum Der Ludwig-Maximilians-Universitat MunchenMunchenGermanyThird party
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyParticipant
Universitatsklinikum ErlangenErlangenGermanyParticipant
Turun YliopistoTurkuFinlandParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Istituto Zooprofilattico Sperimentale Dell'abruzzo E Del Molise G CaporaleTeramoItalyParticipant
Universita Degli Studi Di PadovaPadovaItalyParticipant
Omniscope LimitedMostaMaltaParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsAssociatedpartner
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI